Choosing BTKi or BCL2i or Combination Therapy for 1L CLL

Danielle Brander

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

Year in Review 2024: CLL Highlights

The University of Kansas Cancer Center

M. Hoffmann

Clinical Practice Updates in CLL/SLL

Integrity CE

M. Cortese, D. Wallace, A. Niu

ASH 2025 Review: Acalabrutinib + Venetoclax +/- Obinutuzumab vs. Che…

University of Colorado Division of Hematology

M. Kamdar

ASH 2024 Insights: Ph 3 AMPLIFY - Fixed-Duration Acalabrutinib + Ven…

2024 ASH Annual Meeting Insights Hub

J. Brown

ASH 2024 Summary: Clinical Application of Practice-Changing Abstract…

2024 ASH Annual Meeting Insights Hub

K. Rogers, J. Woyach

1L Therapy in CLL: What Are the Best Options?

SOHO Brazil 2024

J. Burger

Emerging Trends in the Treatment Landscape of CLL

Moffitt Cancer Center

J. Pinilla-Ibarz

CLL in 2024: Evolution of the Role of Novel Targeted Therapies

Louisville Hematology Highlights

C. Coombs

The Future of CLL Treatment: Combination Therapies, Overcoming Resis…

MyCancerHaven

R. Vij, A. Kittai

Debates in CLL: Continuous or Finite Duration Therapy

XV Eurasian Hematology-Oncology Congress - EHOC 2024

N. Jain

Approach to Treatment Selection and Personalization in 1L CLL

Dima El-Sharkawi

ASH 2024 Insights: Zanubrutinib, Obinutuzumab, and Venetoclax (BOVen…

2024 ASH Annual Meeting Insights Hub

J. Soumerai

3L in CLL: The Best Options in a Patient Double-Refractory to Covale…

SOHO Brazil 2024

J. Burger

Pirtobrutinib Updates in CLL - Considerations for Practice

Penn Medicine Abramson Cancer Center

J. Svoboda

Sequencing Therapies in CLL: The Importance of First-Line Treatment …

Nicole Lamanna

Current Guideline-Informed Treatment of CLL

Fred Hutchinson Cancer Center

C. Ujjani

CLL Treatment Sequencing: The Importance of First Choice

City of Hope

S. Rosen

Practice-Changing Updates in Indolent B-Cell Lymphomas

Massachusetts General Hospital Cancer Center

J. Soumerai